As a leading enterprise in China's plant extract industry, Chenguang Biotech Group Co., Ltd. has been deeply involved in the field of natural extracts for over two decades. Driven by technological innovation, it has broken through numerous industry barriers and reshaped the global plant extract industry landscape. Recently, Lu Ying, General Manager of Chenguang Biotech, stated in an interview that the company's development over the past two decades is a history of continuous iteration and persistent innovation. In the future, the company will continue to focus on technological innovation, promoting the upgrading of the plant extract industry towards high-end, diversified, and international markets, and creating a new landscape for high-quality development.
In Lu Ying's view, innovation is the core secret for private enterprises to establish themselves in the industry and lead the market, and it is also a key lever for the plant extract industry to break through homogeneous competition and achieve transformation and upgrading. Having been rooted in the industry for many years, Chenguang Biotech has consistently adhered to using technological innovation to solve industry pain points. Relying on continuous R&D investment and technological iteration, it has achieved a leapfrog transformation from traditional extensive processing to modern refined extraction. Through integrated innovation, the company built China's first continuous, large-scale chili processing production line, achieving a hundredfold increase in production efficiency. By continuously iterating and innovating to reduce costs and increase efficiency, it raised my country's global market share of capsicum red pigment from less than 2% to over 80%, completely dominating the global industry discourse in this niche sector and setting an international benchmark for Chinese plant extracts.
Looking back at the complex and volatile domestic and international market environment in 2025, Chenguang Biotech delivered an impressive performance thanks to its solid innovation foundation and comprehensive product portfolio. The company's core product advantages continued to be consolidated, with sales of capsicum red and capsicum oleoresin both reaching record highs. The nutritional extracts and spice extracts segments steadily improved in quality and expanded in scale, with silymarin and Sichuan pepper extract achieving top global sales volumes, filling the market gap for related high-end products in China. Simultaneously, the company conducted specialized technical research on stevia products, successfully overcoming cost bottlenecks, significantly enhancing product market competitiveness, driving sales of this category to new highs, and continuously strengthening the overall industry resilience and market risk resistance.
Unlike traditional industry models, Chenguang Biotech has established an innovation mechanism where "R&D follows the market and technology revolves around demand," ensuring that technological innovation precisely addresses market needs. Lu Ying explained that the company consistently uses customer pain points as a breakthrough point for innovation, focusing on practical application challenges in downstream food and health industries, and undertaking targeted projects for precise problem-solving. Addressing the common pain point of foaming extracts in the production of hot pot base and seasonings, the R&D team quickly optimized raw material formulas, screened suitable emulsifiers, and repeatedly adjusted production processes, successfully developing a non-foaming dedicated extract product. Upon its launch, it gained high market recognition, achieving a deep integration of technological innovation and market demand. Simultaneously, the company has abandoned the single-raw-material extraction model, achieving multi-component and multi-product extraction from single raw materials through technological upgrades, significantly improving the comprehensive utilization rate of raw materials and product added value, and driving the iterative upgrading of industry production models.
Continuous and stable R&D investment is the solid support for Chenguang Biotech's iterative innovation. For many years, the company has maintained a high level of R&D investment, with annual R&D expenses consistently accounting for 3% to 5% of sales revenue, providing ample support for technological breakthroughs, new product development, andte chnology transfer. Relying on a comprehensive R&D system, the company has built a fully functional pilot-scale platform, opening up a complete transformation channel from laboratory small-scale testing and pilot-scale amplification to large-scale mass production, effectively solving the industry problem of difficulty in applying scientific research results and slow industrialization. In the past three years, the company's pilot-scale platform has completed 162 pilot-scale service projects, achieving the industrialization of 53 technological achievements and successfully implementing 12 high-quality scientific research results in the Beijing-Tianjin region, continuously driving the innovation and upgrading of the regional plant extract industry cluster.
Based on the new development stage in 2026, Lu Ying clarified the company's new round of development strategy. Chenguang Biotech will accelerate its "three-step" development strategy, continuously consolidating its absolute global leading advantage in capsicum red pigment, deeply exploring its advantages in cost control and market channels, focusing on potential sub-categories such as curcumin and steviol glycosides, concentrating core resources on technological breakthroughs and market expansion, striving to create about ten core products that are number one globally or among the top in the industry, and fully building a world-class natural extract industry base.
Building upon its core business of plant extraction, the company will leverage its core separation and extraction technologies to continuously extend its industrial chain into the broader health industry, focusing on health foods and the modernization of traditional Chinese medicine extraction. Through stringent standards for ingredient content control, it will develop high-value-added end-product health products, striving to reverse the current industry situation of low-priced exported plant raw materials and high-priced imported high-end health products, and promoting the modernization, industrialization, and internationalization of traditional Chinese medicine extraction technology. To ensure the implementation of its strategy, the company is fully committed to building three major centers: an internationally leading R&D center, a fully functional pilot-scale testing center, and an authoritative testing center, comprehensively strengthening the foundation for industrial innovation.
Regarding the future development of the industry, Lu Ying stated that the plant extraction industry is an important component of the broader health industry, aligning with the trend of upgrading national health consumption and the development orientation of green and low-carbon industries. In the future, Chenguang Biotech will continue to adhere to the main theme of high-quality development, deeply cultivate the technology track of natural pigments replacing synthetic pigments, and lead the industry's green upgrade through technological innovation; continuously enrich its high-end customized product matrix, optimize its industrial structure, extend its industrial chain, and continuously enhance the global competitiveness and brand influence of China's plant extraction industry, empowering industrial upgrading through pragmatic innovation and injecting Chinese strength into the development of the global health industry.
Shaanxi Lvke Chunyuan Biotechnology Co., Ltd.
Our address
Huaxia Yue World, Weibin District, Baoji City, Shaanxi Province,china
Phone Number
86-13992760792( Grace liu Sales manager )
sales04@lucynatural.com
